drugset / Trial / NCT00638989

A Study to Assess Bioavailability and Pharmacokinetics of CAT- 354

NCT00638989

Phase 1 Completed 30 enrolled MedImmune LLC
RandomizedParallel-groupOpen-labelTreatment

Summary

To compare bioavailability and pharmacokinetics of CAT-354 following subcutaneous administration compared with intravenous administration.

Timeline

Start
2008-04-11
Primary completion
2008-06-07
Completion
2008-06-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Tralokinumab Monoclonal antibody 150 mg Intravenous
Subject Tralokinumab Monoclonal antibody 300 mg Intravenous

Indications